Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multicenter Study to Evaluate the Safety and Efficacy of AGN-151586 for the Treatment of Glabellar Lines

Next Previous
Search
Trial Profile

A Phase 3, Multicenter Study to Evaluate the Safety and Efficacy of AGN-151586 for the Treatment of Glabellar Lines

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 30 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Botulinum toxin E (Primary)
  • Indications Glabellar lines
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors AbbVie; Allergan

Most Recent Events

  • 24 Apr 2025 According to an AbbVie media release, the company announced submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for trenibotulinumtoxinE (TrenibotE) for the treatment of moderate to severe glabellar lines based on M21-500, M21-508 and M21-509.
  • 24 Oct 2023 According to an Allergan Aesthetics media release, additional study results will be submitted for presentation at future medical meetings.
  • 24 Oct 2023 Positive topline results presented in the Allergan Aestheticsin Media Release.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top